Since December 2025, one of the most popular ingredients in the field of longevity science globally, nicotinamide mononucleotide (NMN), has officially been listed as a permissible therapeutic ingredient under Australia’s Therapeutic Goods Administration (TGA).
The TGA — comparable to the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) – is regarded as one of the most rigorous and conservative therapeutic goods regulators worldwide.
This milestone marks the first time NMN has been legally permitted as a therapeutic ingredient for human consumption in Australia and the world, setting a notable global precedent after years of debate over its status as a dietary supplement versus a therapeutic ingredient.
Longevity Life Sciences (LLS), the Australian biotechnology company that prompted the establishment of one of the world’s first regulated frameworks for pharmaceutical-grade NMN, is currently the only company in Australia permitted to supply NMN – under CellVive NMN – an ingredient to manufacturers for use in products intended for Australian consumption.
A global innovator in NMN, the Australian company is set to expand into Asia in the coming months.
Sally Panton, founder and CEO of Longevity Life Sciences, said the announcement represents the culmination of years of collaborative work between scientific, academic and regulatory partners.
“The TGA’s inclusion of NMN as a permissible ingredient reflects the level of scientific and regulatory rigour required to advance this category responsibly. It establishes a credible pathway for access in Australia and reinforces Australian-sourced NMN as a trusted benchmark across the region.”
Lucy Canny, founder and Chief Operating Officer, said: “This decision paves the way for NMN to enter the market transparently and with greater safety mechanisms, giving consumers and our industry partners confidence in the ingredient’s quality and evidence base.”
NMN and the UK: NMN remains available as a supplement, but is not authorised as a medicine
NMN is a molecule that helps the body replenish NAD+ levels, which are essential for energy production and DNA repair. It can be taken as an oral supplement to support NAD+ production.
Hailed as an antiageing hero, NMN has become a sought-after ingredient among consumers globally interested in healthy ageing.
In the UK, NMN is not authorised by the MHRA as a medicinal ingredient and is instead regulated under food and novel food frameworks, with MHRA oversight applying only where medicinal or therapeutic claims are made.
This approach is broadly similar to that of the United States (US), where the US Food and Drug Administration (FDA) had previously ruled that NMN could not be sold as a
dietary supplement ... but has recently reversed that decision, highlighting the rapidly evolving global regulatory landscape surrounding the compound.
Despite limited regulatory mechanisms in place, UK consumer interest remains strong. Monthly online searches for NMN in the UK average approximately 22,900, with individuals aged 35 to 44 accounting for 62.5% of this interest, whereas 48% of searches for the scientific term “NMN” come from those aged 18 to 24, reflecting significant consumer curiosity and growing demand.
By 2035, the global NMN market is projected to reach $3.9 billion in value.
Broad consumer access through Australia’s largest pharmacy network
Following regulatory approval, NMN-containing products formulated with CellVive NMN are now available nationwide through Chemist Warehouse, Australia’s largest pharmacy retail chain, widely regarded as the Australian equivalent of Boots in terms of scale, consumer reach and trust.
This nationwide rollout marks the first time regulated NMN products have been distributed through a mainstream pharmacy network, significantly expanding consumer access via established, pharmacy-led retail channels.
Daniel Kinder, Chemist Warehouse’s Head of Vitamins, said the healthy ageing category has seen sustained growth within Australia in recent years, indicating increased consumer interest in preventative health measures.
“The availability of NMN products through mainstream pharmacy retail supports broader access to an ingredient that, for Australians, until now, had not been accessible, affordable or appropriately vetted for quality,” said Daniel.
“Making NMN products accessible matters because healthy ageing should not become a premium-only intervention: affordability, trusted quality and clear education can help to broaden the understanding of NMN and its role as a widely available ingredient, rather than something limited to niche or elite consumers.”